Nastech Licenses RNAi IP From City of Hope to Develop siRNA Drugs

Nov 08, 2006

NEW YORK (GenomeWeb News) — Nastech Pharmaceutical has licensed RNAi intellectual property and technology from the City of Hope, the company said today.

Nastech licensed City of Hope’s Dicer-Substrate RNA patents and technology in order to develop short-interfering RNA-based drugs for diseases related to protein over-production.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Helix Launches 'App Store'

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

More CAR-T Therapies Sought

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Telomeres of Spawning Salmon

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

This Week in PLOS

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Featured White Papers

High Throughput RT-qPCR for Gene Expression Analysis

Main menu